Sep 2026
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP‐1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double‐Blind, Placebo‐Controlled Trial
To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of the dual GLP‐1R/GIPR agonist BGM0504 in Chinese adults with overweight or obesity without diabetes.
L. Ji, Guo-Ping Yang, Yang-Qing Huang et al.
· Diabetes, obesity and metabo... · 0 citations